AMORPHOUS TELITHROMYCIN COMPOUND
    1.
    发明公开
    AMORPHOUS TELITHROMYCIN COMPOUND 审中-公开
    稳定的无定形泰利CONNECTION

    公开(公告)号:EP1973924A1

    公开(公告)日:2008-10-01

    申请号:EP07700180.8

    申请日:2007-01-04

    申请人: SANDOZ AG

    IPC分类号: C07H17/08 A61K31/7048

    CPC分类号: C07H17/08

    摘要: The present invention relates to stable amorphous 3-De[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L- ribohexopyranosy l)oxy]- 1 1 , 12-dideoxy-6-O-methy 1-3-oxo- 12,11 -[oxycarbonyl[[4-[4-(3-pyridinyl)- 1 H- imidazol-l-yl]butyl]imino]]erythromycin (telithromycin), methods for the preparation thereof, the use of stable amorphous telithromycin in the treatment of bacterial infections and to pharmaceutical compositions comprising stable amorphous telithromycin.

    SALTS OF ARIPIPRAZOLE
    2.
    发明公开
    SALTS OF ARIPIPRAZOLE 有权
    一种制备阿立哌唑的过程

    公开(公告)号:EP1844036A1

    公开(公告)日:2007-10-17

    申请号:EP06704096.4

    申请日:2006-01-27

    申请人: SANDOZ AG

    IPC分类号: C07D401/12 A61K31/496

    CPC分类号: C07D215/227 C07B2200/13

    摘要: The present invention relates to acid addition salts of aripiprazole , a process for preparing said acid addition salts and their use to prepare or purify aripiprazole in the form of a free base or in the form of a pharmaceutically acceptable salt.

    PROCESS FOR THE PRODUCTION OF MYCOPHENOLATE MOFETIL
    4.
    发明公开
    PROCESS FOR THE PRODUCTION OF MYCOPHENOLATE MOFETIL 有权
    生产霉酚酸酯的方法MOFETIL

    公开(公告)号:EP1667987A2

    公开(公告)日:2006-06-14

    申请号:EP04765061.9

    申请日:2004-09-10

    申请人: SANDOZ AG

    IPC分类号: C07D307/88

    CPC分类号: C07D307/88

    摘要: The present invention relates to a new and economically attractive process for the production of mycophenolate mofetil in a high degree of pharmaceutically acceptable purity, which comprises the reaction of a reactive derivative of mycophenolic acid with 4-(2-hydroxyethyl)morpholine under acidic reaction conditions and the subsequent extraction of the pure mycophenolate mofetil through salt formation and release of the free base. A further aspect of the invention relates to the purification of mycophenolate mofetil by removing its by products, in particular its dimeric by-products, by means of treatment with a primary or secondary amine.

    摘要翻译: 本发明涉及一种以高度药学上可接受的纯度生产霉酚酸吗啉乙酯的新的且经济上有吸引力的方法,其包括霉酚酸的反应性衍生物与4-(2-羟乙基)吗啉在酸性反应条件下反应 并随后通过盐形成和游离碱的释放来提取纯麦考酚酸吗乙酯。 本发明的另一方面涉及通过用伯胺或仲胺处理除去其副产物,特别是其二聚副产物来纯化麦考酚酸吗啉乙酯。

    CRYSTALLINE FORM OF ALOGLIPTIN
    5.
    发明授权
    CRYSTALLINE FORM OF ALOGLIPTIN 有权
    ALOGLIPTIN的结晶形式

    公开(公告)号:EP2379522B1

    公开(公告)日:2018-02-28

    申请号:EP09784096.1

    申请日:2009-12-18

    申请人: Sandoz AG

    IPC分类号: C07D401/04

    CPC分类号: C07D401/04

    摘要: The present invention is directed to a crystalline form of 2-[6-[3(R)-aminopiperidin-1-yl]-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-ylmethyl]-benzonitrile, a process for the preparation of said crystalline form and the use thereof in the manufacture of a pharmaceutical composition.

    A CEFDINIR INTERMEDIATE
    6.
    发明授权
    A CEFDINIR INTERMEDIATE 有权
    中间头孢地尼

    公开(公告)号:EP1554289B1

    公开(公告)日:2011-03-09

    申请号:EP03787771.9

    申请日:2003-08-12

    申请人: SANDOZ AG

    IPC分类号: C07D501/00 A61K31/546

    CPC分类号: C07D501/00

    摘要: 7-[2-(2-aminothiazol-4-yl)-2-(methylcarbonyloxyimino)acetamido]-3-vinyl-cephem-4-carboxylic acid of formula (I), in the form of a crystalline salt and use thereof, e.g. in the preparation of pure cefdinir. In another aspect this invention relates to the compound of formula (I) in the form of a salt, optionally in crystalline form, wherein the salt is selected from the group consisting of phosphate, hydrogen phosphate, mesylate, tosylate, sulfate, hydrogen sulfate and sulfamate.

    NOVEL POLYMORPHS OF APREPITANT AND PROCESSES FOR PREPARATION
    7.
    发明公开
    NOVEL POLYMORPHS OF APREPITANT AND PROCESSES FOR PREPARATION 审中-公开
    阿瑞和方法的新多晶型

    公开(公告)号:EP2129671A2

    公开(公告)日:2009-12-09

    申请号:EP08717054.4

    申请日:2008-02-22

    申请人: Sandoz AG

    CPC分类号: C07D413/06

    摘要: Novel polymorph form III of Aprepitant and a method for preparation of novel form III is disclosed. New processes for the preparation of Aprepitant form II are disclosed. The processes involve transformation of form III to form II by heating in decalin and the precipitation of form II from a solvent or solvent mixture by cooling and/or addition of addition of seed crystals or an anti solvent. Solid dispersions containing Aprepitant form II in a suitable carrier are disclosed. A process for the preparation of the solid dispersion by evaporation of a solution of Aprepitant and the carrier in a suitable solvent is disclosed. Stable Aprepitant form II is disclosed. Further pharmaceutical compositions containing Aprepitant form II, III or solid dispersions containing Aprepitant form II in a suitable carrier are disclosed. A methanol solvate of Aprepitant is disclosed.

    CRYSTALLINE FORM OF CINACALCET
    8.
    发明公开
    CRYSTALLINE FORM OF CINACALCET 审中-公开
    西那卡塞晶型

    公开(公告)号:EP2064173A1

    公开(公告)日:2009-06-03

    申请号:EP07785846.2

    申请日:2007-06-25

    申请人: Sandoz AG

    IPC分类号: C07C211/30 A61K31/135

    CPC分类号: C07C211/30

    摘要: The present invention relates to the polymorph form II of Cinacalcet hydrochloride, methods for the preparation of pure form II of Cinacalcet hydrochloride, and pharmaceutical compositions comprising the new polymorphic form in an pharmaceutically effective amount The present invention also provides novel solvates of Cinacalcet hydrochloride, methods for the preparation of these solvates, the use of these novel solvates for the preparation of pure Cinacalcet hydrochloride, the use of these novel solvates for the preparation of polymorphic form II of Cinacalcet hydrochloride and pharmaceutical compositions comprising the acetic acid solvate of Cinacalcet hydrochloride.